AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Abivax: JMP Securities maintains a 'Market Outperform' Rating, The Target Price is $95
ByAinvest
Wednesday, Jul 23, 2025 8:00 am ET1min read
JMP Securities maintains 'Market Outperform' rating on Abivax(ABVX).
The target price is $95, compare with $33 previously.
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-07-23 | Guggenheim | Maintains | Buy | Buy | $101 | $50 |
| 2025-07-23 | LifeSci Capital | Maintains | Outperform | Outperform | $101 | $45 |
| 2025-07-23 | JMP Securities | Maintains | Market Outperform | Market Outperform | $95 | $33 |
| 2025-07-23 | Piper Sandler | Maintains | Overweight | Overweight | $70 | $42 |
[Recent Earning Results] Abivax posted the Q1 of its 2025 financial results on 6/2/2025, reporting total revenue of EUR 0.99 million in the first quarter, down 16.19% from EUR 1.19 million year over year, reporting net income of EUR -52.37 million in the first quarter, expanding 22.17% from EUR -42.87 million year over year.
[Company Profile] Abivax Sa is incorporated under the laws of France on December 4, 2013. The company is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is currently evaluating lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet